You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, February 2013
|
| DOI | 10.1186/1750-1172-8-26 |
| Pubmed ID | |
| Authors |
Maggie C Walter, Peter Reilich, Simone Thiele, Joachim Schessl, Herbert Schreiber, Karlheinz Reiners, Wolfram Kress, Clemens Müller-Reible, Matthias Vorgerd, Peter Urban, Bertold Schrank, Marcus Deschauer, Beate Schlotter-Weigel, Ralf Kohnen, Hanns Lochmüller |
| Abstract |
Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B). |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | <1% |
| Unknown | 118 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 20 | 17% |
| Student > Ph. D. Student | 17 | 14% |
| Researcher | 15 | 13% |
| Student > Bachelor | 11 | 9% |
| Other | 11 | 9% |
| Other | 19 | 16% |
| Unknown | 26 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 32% |
| Agricultural and Biological Sciences | 13 | 11% |
| Biochemistry, Genetics and Molecular Biology | 11 | 9% |
| Nursing and Health Professions | 6 | 5% |
| Neuroscience | 6 | 5% |
| Other | 14 | 12% |
| Unknown | 31 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 206. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2023.
All research outputs
#189,633
of 25,371,288 outputs
Outputs from Orphanet Journal of Rare Diseases
#15
of 3,105 outputs
Outputs of similar age
#1,300
of 296,584 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#1
of 47 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,584 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.